Trial reportBlood cancer journal2024
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
Trial report in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.Blood neoplasia · 2025Trial
- MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.Blood advances · 2025Trial
- Blood metabolic profiling associated with a short-term intensive training period in elite male water polo athletes: an exploratory metabolomics study.Journal of the International Society of Sports Nutrition · 2026Article
- Clinical applications of mass spectrometry in multiple myeloma.Blood advances · 2025Review
- What is the best induction for myeloma for the fit patient?Hematology. American Society of Hematology. Education Program · 2025Review
- Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy.Annals of hematology · 2025Article
- Review
- Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.HemaSphere · 2025Article
- Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.HemaSphere · 2025Review
- Review
- Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q.Cancers · 2025Article
- Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies.Annals of hematology · 2025Review
- Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?Blood cancer journal · 2024Article
- Chimeric antigen receptor T-cell therapy in autoimmune diseases.Frontiers in immunology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
We evaluated the efficacy and safety of 24 cycles of Dara in combination with carfilzomib (K), lenalidomide (R), and dexamethasone (d) without autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) irrespective of ASCT eligibility in a single-arm, phase II study. The primary endpoint was the rate of stringent complete response (sCR) and/or measurable residual disease (MRD) < 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.